Sonion and Valencell Partner to Make Biometrics Universal in Hearables and Hearing Health Markets
Sonion, the global leader in micro acoustic and micro mechanical technologies and solutions for hearing instruments and specialty earphones, and Valencell, the leading innovator in wearable biometric sensor technology, today announced a strategic partnership that will expand the boundaries for the use of biometric sensors in the ear. In the partnership Valencell provides the industry’s most advanced biometric sensor modules for hearables and wearables, which Sonion will optimize for size, power consumption and cost for in-ear and on-ear applications. The partnership focuses on designing, developing and manufacturing biometric sensing ear modules for the medical, hearing health, consumer and professional communications markets.
The partnership leverages Valencell’s expertise and experience as a leader in wearable biometrics and Sonion’s more than 40 years of experience as a leader in the development and manufacturing of products for the hearing health market. Under the partnership, Sonion will introduce a wide range of sensor modules for different applications in the ear and Valencell will continue to further develop its innovative portfolio of advanced, accurate biometric sensor capabilities for all form factors. Sonion will also integrate its world class balanced armature speakers among other components as part of the sensor modules.
Sonion’s manufacturing expertise in miniaturized components for ear-based devices is expected to result in significant reductions to the size, cost and power consumption of photoplethysmography (PPG)-based sensors for continuous heart rate, blood pressure, and other medical monitoring and fitness/wellness related functionalities into hearables, hearing aids and other ear-level devices.
The markets for hearables and hearing health devices are both predicted to show a steady growth. The consumer hearables segment is expected to grow at 48% CAGR through 2022, according to IDC, while the hearing health market is expected to continue to demonstrate stable growth numbers and increase 22% over the same period according to OrbisResearch.com
In addition, as part of the partnership, Sonion has made a strategic investment of an undisclosed amount in Valencell, making Sonion a significant shareholder in Valencell Inc.
“I am truly excited about the partnership with Valencell,” says Jesper Ahlmann Funding Andersen, President & CEO of Sonion a/s. “We are bringing the best of two worlds together. Biometric sensing is the next big thing for many of our customers, making the ear-level devices truly multi-functional. Joining forces with the global leader in this field - Valencell - brings accuracy and the possibility to add innovative new metrics to the products we develop for our customers, including advanced medical monitoring. We look forward to together setting a new standard for what is possible.”
“This partnership with Sonion brings tremendous value to the hearables and hearing health markets, as well as to our current and future customers and partners,” said Michael Dering, CEO of Valencell. “Sonion brings world-class expertise and capabilities in hearing health component development, manufacturing, and distribution. As demonstrated by Valencell’s foundational patents in biometric hearables, since foundation we have envisioned a world where traditional ear-worn devices can be used to improve public health. Valencell and Sonion share a strong vision and operating model for making major advancements in hearing health and hearable devices. We are excited about the great things to come.”
Sonion a/s is a Novo Holding a/s owned global leader in microacoustics and micromechanics for hearing health and other ear-level devices. The company – which is headquartered in Roskilde, Denmark - employs over 5.500 employees across sites in Denmark, Holland, USA, China, Poland, Vietnam and Philippines.
Valencell produces the most accurate wearable biometric sensor systems in the world and provides this patent-protected technology to consumer electronics manufacturers, mobile device and accessory makers, medical device makers, sports and fitness brands and gaming companies for integration into their products. Protected by more than 60 granted patents and more than 100 patents pending, Valencell’s technology can be used in wearables and hearables for virtually anyone, anywhere, doing anything. Their technology is scalable to multiple form-factors such as earbuds, smartwatches, armbands and wrist devices and is currently integrated into more biometric wearable devices than any other technology provider in the world.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Proteus Digital Health® Founder to Present at World Economic Forum in Davos21.1.2019 21:54 | Tiedote
Proteus Digital Health® announced today that Andrew Thompson, its President, Chief Executive Officer and Co-Founder, will present on the progress of Proteus’ digital medicines to improve patient treatment and outcomes at the 2019 World Economic Forum Annual Meeting in Davos-Klosters, Switzerland. Mr. Thompson will present on the official programme: With leaders from financial and academic institutions to address “Theory of the Firm in a World of Digital Ecosystems,” on Tuesday, January 22 beginning at 9:45 a.m. CET in the Congress Centre, Jakobshorn; and Joining state and religious leaders in the Open Forum “Bridging Science with Society,” scheduled to begin at 9:00 a.m. CET on Friday, January 25 at the Swiss Alpine High School Auditorium. This session will be live-streamed on TopLink and the Forum website. Mr. Thompson will also present at two other events during the World Economic Forum Meeting: January 22 at 8:05 p.m., Polish House: Mr. Thompson will provide a keynote address on the
CNIM Is to Equip the French Navy with 14 New Standard Amphibious Landing Craft (EDA-S)21.1.2019 21:36 | Tiedote
CNIM - in partnership with Socarenam, Mauric and CNN MCO - has been awarded the contract to replace the French Navy's landing crafts. Fourteen new Standard Amphibious Landing Crafts (EDA-S) are to be built over a ten-year period. This contract reasserts CNIM's status as a key partner to the French Navy and a European leader in the area of amphibious operations, supplying the complementary innovative vessels: EDA-S and EDA-R (already in service in the French Navy, designed by CNIM). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005420/en/ CNIM is to equip the French Navy with 14 new Standard Amphibious Landing Craft (EDA-S) - (c) CNIM Next-generation of vessels designed by CNIM "Winning this European tender reasserts CNIM's status as experts in amphibious craft design. CNIM is to replace the French Navy's existing landing craft with fourteen new Standard Amphibious Landing Craft, also called EDA-S", notes Philippe Demi
Naspers Progresses Plans to List MultiChoice Group Limited and Unbundle Its Shares in MultiChoice Group to Naspers Shareholders21.1.2019 19:04 | Tiedote
On 17 September 2018, Naspers Limited (JSE: NPN; LSE: NPSN) announced its intention to list its video entertainment business separately on the Johannesburg Stock Exchange (JSE) as MultiChoice Group Limited (MultiChoice Group) and simultaneously unbundle its shares in this business to Naspers shareholders. It is expected that the Admission and dealings in the Shares will commence on Wednesday, 27 February 2019. In relation to the Admission, MultiChoice Group today published a pre-listing statement compliant with the requirements of the JSE. MultiChoice South Africa (MCSA), MultiChoice Africa, Showmax and Irdeto and their subsidiaries and affiliates, will, among others, be subsidiaries of MultiChoice Group. MultiChoice Group is the leading video entertainment operator on the African continent, with an extensive local and international content offering. It is one of the fastest-growing pay-TV broadcast providers globally and provides entertainment to around 14 million households across 50
MultiChoice Group Limited (MCG) Today Released Its Pre-Listing Statement in Compliance with the JSE Listings Requirements21.1.2019 18:59 | Tiedote
Naspers Limited (JSE: NPN; LSE: NPSN) : MultiChoice Group Limited (MCG) today released its pre-listing statement in compliance with the JSE Listings Requirements (www.multichoice.com) providing further details about its listing on the Johannesburg Stock Exchange (JSE). Trading in MCG shares is expected to commence on the JSE on Wednesday, 27 February 2019. As announced on 17 September 2018, MCG will include, amongst others, MultiChoice South Africa (MCSA), MultiChoice Africa, Showmax, as well as the global digital platform security provider, Irdeto and all their subsidiaries and affiliates (“the Group”). Calvo Mawela, Group Chief Executive Officer of MCG said: “We believe the listing of MultiChoice provides an excellent opportunity to invest in the leading provider of video entertainment on the African continent. MCG brings an incomparable local and international content offering to around 14-million households and is one of the fastest growing pay-TV broadcast providers globally. With
ResMed’s First Top-of-Head CPAP Mask, AirFit N30i, Now Available across U.S.21.1.2019 17:05 | Tiedote
ResMed (NYSE: RMD, ASX: RMD), today introduced AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the United States, with a newly designed nasal cradle cushion that sits just under the wearer’s nose. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005035/en/ AirFit N30i nasal CPAP mask, front view (Photo: Business Wire) The top-of-head connection keeps tubing out of the wearer’s way, letting them move and sleep in any position. The nasal cradle cushion – ResMed’s first – is designed to reduce facial markings and irritation. AirFit N30i is also convenient for equipment providers and sleep labs – it fits 96 percent of PAP users with just two frame sizes and four cushion sizes. How AirFit N30i compares to the market-leading nasal top-of-head mask In side-by-side comparisons, three out of four users preferred AirFit N30i over the other nasal mask with a top-of-head connection. A majority stated they loved
Metabolon Appoints Michael Rasche as President of International Business21.1.2019 16:06 | Tiedote
Metabolon, the world leader in metabolomics, today announced that Michael Rasche joined the company as President of International Business. Michael will report to Rohan Hastie, Metabolon’s President and CEO, and become a member of the corporate executive team. He will lead all of Metabolon's international business activities with a strong focus on customer and team expansion. "We are thrilled to have Michael join the Metabolon team," said Hastie. "Michael brings a wealth of commercial and business experience across multiple areas of life sciences, from Pharma to Diagnostics and Biotech. I know he will make an immediate impact on our existing and future customers." "I am very excited to become part of the Metabolon success story," added Rasche. "I will passionately lead our team to drive accelerated business expansion across all international markets. Our Precision Metabolomics™ technology is delivering biomarker discoveries, innovative diagnostic tests, and groundbreaking data in genom
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme